June 27 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE.EDGE THERAPEUTICS - IN STUDY'S PRIMARY ENDPOINT, 45% OF SUBJECTS TREATED WITH A SINGLE INTRAVENTRICULAR INJECTION OF EG-1962 EXPERIENCED A FAVORABLE OUTCOME.EDGE THERAPEUTICS - EXPECTS TO REPORT FINAL ANALYSIS OF DATA FROM ALL 283 SUBJECTS IN NEWTON 2 STUDY WHEN DATA ARE AVAILABLE LATER THIS YEAR.
Full Article

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: